No abstract available
Keywords:
COVID-19; Sézary syndrome; cutaneous lymphoma; high-risk; mycosis fungoides.
MeSH terms
-
Antibiotics, Antineoplastic / therapeutic use
-
Antineoplastic Agents, Immunological / adverse effects
-
Betacoronavirus / immunology
-
Betacoronavirus / isolation & purification
-
COVID-19
-
Chemoradiotherapy / methods
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / immunology*
-
Coronavirus Infections / mortality
-
Coronavirus Infections / virology
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Home Care Services, Hospital-Based
-
Humans
-
Lymphoma, T-Cell, Cutaneous / complications
-
Lymphoma, T-Cell, Cutaneous / immunology
-
Lymphoma, T-Cell, Cutaneous / therapy*
-
Mycosis Fungoides / complications
-
Mycosis Fungoides / immunology
-
Mycosis Fungoides / therapy*
-
Pandemics
-
Patient Selection
-
Photopheresis
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / immunology*
-
Pneumonia, Viral / mortality
-
Pneumonia, Viral / virology
-
Risk Assessment
-
SARS-CoV-2
-
Severity of Illness Index
-
Sezary Syndrome / complications
-
Sezary Syndrome / immunology
-
Sezary Syndrome / therapy*
-
Skin Neoplasms / complications
-
Skin Neoplasms / immunology
-
Skin Neoplasms / therapy*
-
Telemedicine / methods
-
Ultraviolet Therapy
-
United States
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents, Immunological